Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectableLiver Cancer
Interventions
DEVICE

EYE90 Microspheres Treatment

Y90 glass microspheres

Trial Locations (22)

10065

RECRUITING

Weill Cornell Medicine-New York Presbyterian Hospital, New York

19104

RECRUITING

Hospital of the University of Pennsylvania, Philadelphia

28202

RECRUITING

Charlotte Radiology, Charlotte

30308

RECRUITING

Emory University Hospital Midtown, Atlanta

30309

RECRUITING

Piedmont Hospital, Atlanta

32701

RECRUITING

AdventHealth Radiation Oncology at Altamonte Springs, Altamonte Springs

33176

RECRUITING

Miami Cardiac and Vascular Institute at Baptist Hospital Miami, Miami

37203

RECRUITING

HCA Healthcare Research Institute (Sarah Cannon), Nashville

40202

RECRUITING

University of Louisville, Louisville

52242

RECRUITING

University of Iowa Health Care, Iowa City

53226

RECRUITING

Froedtert Hospital/Medical College of Wisconsin, Milwaukee

60611

RECRUITING

Northwestern University Memorial Hospital, Chicago

60612

RECRUITING

University of Illinois Hospital and Health Sciences System, Chicago

63104

RECRUITING

SSM Health Saint Louis University, St Louis

65212

RECRUITING

University of Missouri - Ellis Fischel Cancer Center, Columbia

70121

RECRUITING

Ochsner Clinic Foundation, New Orleans

84112

RECRUITING

University of Utah, Salt Lake City

85719

RECRUITING

The University of Arizona Cancer Center, Tucson

92867

RECRUITING

University of California - Irvine, Orange

99203

RECRUITING

Inland Imaging, Spokane

02215

RECRUITING

Beth Israel Deaconess, Boston

V5Z 1M9

RECRUITING

Vancouver Coastal Health Research Institution (VCHRI), Vancouver

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ABK Biomedical

INDUSTRY

NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter